Literature DB >> 25755556

Hepatitis C virus genotype 3: hope for nonresponders and patients with cirrhosis.

.   

Abstract

Entities:  

Keywords:  SVR; peginterferon; ribavirin; side-effects

Year:  2014        PMID： 25755556      PMCID： PMC4188836          DOI： 10.1016/j.jceh.2014.05.009

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  9 in total

Review 1.  The interaction of metabolic factors with HCV infection: does it matter?

Authors:  Elisabetta Bugianesi; Federico Salamone; Francesco Negro
Journal:  J Hepatol       Date:  2012       Impact factor: 25.083

Review 2.  New hepatitis C therapies: the toolbox, strategies, and challenges.

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2014-03-12       Impact factor: 22.682

3.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Authors:  Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

Review 4.  Global burden of disease (GBD) for hepatitis C.

Authors: 
Journal:  J Clin Pharmacol       Date:  2004-01       Impact factor: 3.126

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

Review 7.  Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.

Authors:  Khayriyyah Mohd Hanafiah; Justina Groeger; Abraham D Flaxman; Steven T Wiersma
Journal:  Hepatology       Date:  2013-02-04       Impact factor: 17.425

8.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

Authors:  Maximilian David Schneider; Christoph Sarrazin
Journal:  Antiviral Res       Date:  2014-02-25       Impact factor: 5.970
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.